FDA approves new COVID-19 shots
The Food and Drug Administration approved updated COVID-19 vaccines on Thursday for people at higher risk, clearing the way for manufacturers to begin shipping them to pharmacies and physicians' offices. The agency greenlit new formulations of the mRNA vaccines from Pfizer-BioNTech and Moderna, the companies said. FDA also approved a non-mRNA shot from Sanofi, which...
The U.S. Food and Drug Administration (FDA) has approved Moderna's updated COVID-19 vaccines, Spikevax and mNEXSPIKE, for the 2026-2027 season, according to a press release from the company. These updated vaccines contain the JN.1-lineage XFG subvariant of SARS-CoV-2, as recommended by the FDA. The 2026-2027 formula for Spikevax has received approval in several countries, including Europe, South Korea, Singapore, Switzerland, and the United Kingdom.
The 2026-2027 formula for mNEXSPIKE has been approved by regulators in Japan. Additional regulatory applications are under review globally. Moderna CEO Stéphane Bancel emphasized that COVID-19 remains a serious public health threat, responsible for numerous outpatient visits and hospitalizations in the U.S. last year alone. The updated vaccines are expected to be available in the coming days.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- FDA approves Moderna’s updated COVID-19 vaccines for 2026-2027 investing.com
- Pfizer, BioNTech win approval for updated COVID-19 shot seekingalpha.com
